'Hyperinflationary' drugs removed from CVS Health's 2017 formulary

4 August 2016

US pharmacy benefits manager CVS Health (NYSE: CVS) is to remove 35 products from its formulary - the list of drugs it supplies – in 2017.

The affected products – which include cancer and diabetes drugs – are excluded as part of CVS Health’s drive to contain costs and embrace biosimilars and follow-on biologics which replace more expensive medicines.

In publishing its standard formulary list of removals and updates, CVS Health describes containing cost as "essential at a time when escalating drug prices as well as the introduction of new costly therapies are creating significant challenges to the affordability of health care.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK